Avestar Capital, LLC Incyte Corp Transaction History

Avestar Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$72.82 - $86.52 $1,820 - $2,163	-25 Closed	0 $0
Q4 2018 Jan 25, 2019	SELL	$58.5 - $69.94 $1,638 - $1,958	-28 Reduced 52.83%	25 $1,000
Q3 2018 Oct 23, 2018	SELL	$61.75 - $74.23 $3,952 - $4,750	-64 Reduced 54.7%	53 $2,000
Q2 2018 Aug 10, 2018	BUY	$60.85 - $83.98 $2,251 - $3,107	37 Added 46.25%	117 $6,000
Q1 2018 May 10, 2018	SELL	$83.06 - $100.98 $4,236 - $5,149	-51 Reduced 38.93%	80 $9,000
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $12,256 - $15,274	131	131 $10,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.2B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Avestar Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Avestar Capital, LLC with notifications on news.